340 related articles for article (PubMed ID: 34550757)
1. Poziotinib for Patients With
Elamin YY; Robichaux JP; Carter BW; Altan M; Gibbons DL; Fossella FV; Lam VK; Patel AB; Negrao MV; Le X; Mott FE; Zhang J; Feng L; Blumenschein G; Tsao AS; Heymach JV
J Clin Oncol; 2022 Mar; 40(7):702-709. PubMed ID: 34550757
[TBL] [Abstract][Full Text] [Related]
2. Poziotinib in Non-Small-Cell Lung Cancer Harboring
Le X; Cornelissen R; Garassino M; Clarke JM; Tchekmedyian N; Goldman JW; Leu SY; Bhat G; Lebel F; Heymach JV; Socinski MA
J Clin Oncol; 2022 Mar; 40(7):710-718. PubMed ID: 34843401
[TBL] [Abstract][Full Text] [Related]
3. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Prelaj A; Bottiglieri A; Proto C; Lo Russo G; Signorelli D; Ferrara R; Galli G; De Toma A; Viscardi G; Brambilla M; Lobefaro R; Nichetti F; Manglaviti S; Occhipinti M; Labianca A; Ganzinelli M; Gallucci R; Zilembo N; Greco GF; Torri V; de Braud F; Garassino MC
Eur J Cancer; 2021 May; 149():235-248. PubMed ID: 33820681
[TBL] [Abstract][Full Text] [Related]
4. Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
Cornelissen R; Prelaj A; Sun S; Baik C; Wollner M; Haura EB; Mamdani H; Riess JW; Cappuzzo F; Garassino MC; Heymach JV; Socinski MA; Leu SY; Bhat G; Lebel F; Le X;
J Thorac Oncol; 2023 Aug; 18(8):1031-1041. PubMed ID: 36958688
[TBL] [Abstract][Full Text] [Related]
5. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
[TBL] [Abstract][Full Text] [Related]
6. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring
Mazieres J; Lafitte C; Ricordel C; Greillier L; Negre E; Zalcman G; Domblides C; Madelaine J; Bennouna J; Mascaux C; Moro-Sibilot D; Pinquie F; Cortot AB; Otto J; Cadranel J; Langlais A; Morin F; Westeel V; Besse B
J Clin Oncol; 2022 Mar; 40(7):719-728. PubMed ID: 35073148
[TBL] [Abstract][Full Text] [Related]
7. Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
Oh IJ; Hur JY; Park CK; Kim YC; Kim SJ; Lee MK; Kim HJ; Lee KY; Lee JC; Choi CM
Clin Lung Cancer; 2018 Sep; 19(5):e775-e781. PubMed ID: 30149884
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
9. Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials.
Wang BC; Kuang BH; Liu XX; Lin GH
Medicine (Baltimore); 2022 Nov; 101(44):e31337. PubMed ID: 36343036
[TBL] [Abstract][Full Text] [Related]
10. Pyrotinib in
Zhou C; Li X; Wang Q; Gao G; Zhang Y; Chen J; Shu Y; Hu Y; Fan Y; Fang J; Chen G; Zhao J; He J; Wu F; Zou J; Zhu X; Lin X
J Clin Oncol; 2020 Aug; 38(24):2753-2761. PubMed ID: 32614698
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Robichaux JP; Elamin YY; Tan Z; Carter BW; Zhang S; Liu S; Li S; Chen T; Poteete A; Estrada-Bernal A; Le AT; Truini A; Nilsson MB; Sun H; Roarty E; Goldberg SB; Brahmer JR; Altan M; Lu C; Papadimitrakopoulou V; Politi K; Doebele RC; Wong KK; Heymach JV
Nat Med; 2018 May; 24(5):638-646. PubMed ID: 29686424
[TBL] [Abstract][Full Text] [Related]
12. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
Koga T; Kobayashi Y; Tomizawa K; Suda K; Kosaka T; Sesumi Y; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Suzuki M; Jänne PA; Mitsudomi T
Lung Cancer; 2018 Dec; 126():72-79. PubMed ID: 30527195
[TBL] [Abstract][Full Text] [Related]
13. Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?
Borm FJ; Smit EF
J Thorac Oncol; 2023 Aug; 18(8):964-966. PubMed ID: 37479324
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.
Song Z; Li Y; Chen S; Ying S; Xu S; Huang J; Wu D; Lv D; Bei T; Liu S; Huang X; Xie C; Wu X; Fu J; Hua F; Wang W; Xu C; Gao C; Cai S; Lu S; Zhang Y
BMC Med; 2022 Feb; 20(1):42. PubMed ID: 35101045
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
16. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
Kris MG; Camidge DR; Giaccone G; Hida T; Li BT; O'Connell J; Taylor I; Zhang H; Arcila ME; Goldberg Z; Jänne PA
Ann Oncol; 2015 Jul; 26(7):1421-7. PubMed ID: 25899785
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab Deruxtecan in
Li BT; Smit EF; Goto Y; Nakagawa K; Udagawa H; Mazières J; Nagasaka M; Bazhenova L; Saltos AN; Felip E; Pacheco JM; Pérol M; Paz-Ares L; Saxena K; Shiga R; Cheng Y; Acharyya S; Vitazka P; Shahidi J; Planchard D; Jänne PA;
N Engl J Med; 2022 Jan; 386(3):241-251. PubMed ID: 34534430
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Cho JH; Lim SH; An HJ; Kim KH; Park KU; Kang EJ; Choi YH; Ahn MS; Lee MH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Clin Oncol; 2020 Feb; 38(5):488-495. PubMed ID: 31825714
[TBL] [Abstract][Full Text] [Related]
20. Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
Fan Y; Chen J; Zhou C; Wang H; Shu Y; Zhang J; Hua H; Huang DC; Zhou C
Lung Cancer; 2020 Sep; 147():209-213. PubMed ID: 32738416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
